Revenues grew by 3.4 percent to $4.48 billion from $4.33 billion year-on-year, on the back of strong growth across its brands ...

Teva Pharmaceutical Industries Limited ( ($TEVA) ) has released its Q3 earnings. Here is a breakdown of the information Teva Pharmaceutical ...

Teva Pharmaceutical (TEVA) delivered a compelling performance in the third quarter, with financial results exceeding market expectations. The company reported quarterly revenue of $4.48 billion, a 3% ...

In its third quarter, Teva booked revenue of $4.48 billion. That was 3% higher year over year, and much of that growth came ...

Teva Pharmaceutical CEO Richard Francis speaks about 3Q earnings on Bloomberg BusinessWeek with Bloomberg's Katie Greifeld ...

Even with Inflation Reduction Act (IRA)-related pressure looming for its top product, Teva Pharmaceuticals is continuing to ...

Teva Pharmaceutical is one of the leading global generic drug manufacturers. By our estimate, roughly 70% of its total revenue is derived from generics and off-patent branded drugs. Generic drugs in ...

Executive VP Eric Hughes described the pipeline's late-stage assets, including olanzapine LAI on track for FDA submission, DARI, duvakitug, and emrusolmin, citing potential peak sales of over $11 ...

Teva Pharmaceuticals has a new game plan for raising awareness of tardive dyskinesia (TD). | Teva Pharmaceuticals has a new ...

Toast Inc (NYSE: TOST) gained 9.3% to $39.00 after the company reported better-than-expected quarterly financial results. Also, Morgan Stanley maintained an Overweight rating on the stock and raised ...

Teva shares jumped 12% after Q3 earnings beat estimates, driven by strong branded drug sales led by Austedo and solid guidance for 2025.

Teva Q3 revenue rose to $4.48 billion, beating estimates, as Austedo and Ajovy boosted growth; 2025 EPS outlook now ...